Osaka study of Nicorandil effect on Chronic Kidney Disease

Osaka study of Nicorandil effect on Chronic Kidney Disease - ON-CKD study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001508

Enrollment

Registered

2009-01-10

Start date

2009-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease Ischemic coronary disease

Interventions

Nicorandil, 15mg/day, per os No use of nicorandil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Age, above 20 and below 75 (2)Chronic kidney disease. (3)Patients with angina or silent myocardial ischemia (4) Patients with endothelial dysfunction (5) Patients who are obtained informed consent

Exclusion criteria

Exclusion criteria: (1)Liver cirrhosis (2)Previous organ transplantation (3)Administered anti-cancer drugs within 2 years (4)Non Japanese (5)Known HIV/AIDS

Design outcomes

Primary

Measure	Time frame
Endothelial function measured by reactive hyperemia by pulse amplitude tonometry (RH-PAT) and augmentation index and cardiac stress marker.	—

Secondary

Measure	Time frame
The primary end point is death from all causes, morbidity and mortality from cardiovascular causes, a composite of myocardial infarction, stroke, first hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, or death from cardiovascular causes. The time to the first event of the composite end point of a doubling of the serum creatinine concentration, end-stage renal disease, or death is also set as a primary end point.	—

Measure

Time frame

The primary end point is death from all causes, morbidity and mortality from cardiovascular causes, a composite of myocardial infarction, stroke, first hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, or death from cardiovascular causes. The time to the first event of the composite end point of a doubling of the serum creatinine concentration, end-stage renal disease, or death is also set as a primary end point.

—

Countries

Japan

Contacts

Public ContactYoshitaka Isaka

Osaka University Hospital Department of Nephrology

y-isaka@kid.med.osaka-u.ac.jp06-6879-3632

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026